TC
ARQT icon

Tejara Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Tejara Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
113,084
-53,107
-32% -$1.24M 1.22% 24
2026
Q1 		$3.92M Buy
+166,191
New +$4.24M 1.29% 27
2025
Q4 		– Sell
-520,503
Closed -$9.81M – 64
2025
Q3 		$9.81M Sell
520,503
-352,878
-40% -$5.57M 5.12% 3
2025
Q2 		$12.2M Buy
873,381
+27,160
+3% +$381K 5.68% 2
2025
Q1 		$13.2M Sell
846,221
-40,617
-5% -$572K 5.11% 2
2024
Q4 		$12.4M Sell
886,838
-278,471
-24% -$3.05M 8.09% 1
2024
Q3 		$10.8M Sell
1,165,309
-178,300
-13% -$1.76M 5.16% 3
2024
Q2 		$12.5M Buy
1,343,609
+403,122
+43% +$3.65M 4.54% 3
2024
Q1 		$9.32M Sell
940,487
-171,730
-15% -$1.28M 3.42% 7
2023
Q4 		$3.59M Buy
1,112,217
+803,038
+260% +$2.18M 1.5% 25
2023
Q3 		$1.64M Buy
309,179
+145,000
+88% +$1.23M 0.93% 32
2023
Q2 		$1.56M Buy
164,179
+66,179
+68% +$735K 0.77% 34
2023
Q1 		$1.08M Buy
98,000
+40,000
+69% +$579K 0.55% 44
2022
Q4 		$858K Buy
+58,000
New +$1.01M 0.49% 49

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tejara Capital's ARQT Position: Q2 2026 in Review

Tejara Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 32% in Q2 2026, selling an estimated $1.24M and leaving 113,084 shares worth $2.97M. The position accounts for 1.22% of the portfolio, ranked #24.

Tejara Capital first reported a position in ARQT in Q4 2022 and has held it in 14 quarters since. The position peaked at $13.2M in Q1 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Tejara Capital held 113,084 shares of Arcutis Biotherapeutics worth $2.97M as of Q2 2026.
  • Tejara Capital sold 53,107 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.24M.
  • Arcutis Biotherapeutics made up 1.22% of Tejara Capital's portfolio in Q2 2026, its #24 holding.
  • Tejara Capital first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 14 quarters since.
  • Tejara Capital's Arcutis Biotherapeutics position peaked at $13.2M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.